Exagen Inc. (XGN)
4.03
0.15 (3.87%)
At close: Mar 24, 2025, 3:54 PM
3.94
-2.24%
After-hours: Mar 24, 2025, 07:55 PM EDT
3.87% (1D)
| Bid | 3.71 |
| Market Cap | 72.17M |
| Revenue (ttm) | 54.04M |
| Net Income (ttm) | -14.68M |
| EPS (ttm) | -0.83 |
| PE Ratio (ttm) | -4.86 |
| Forward PE | -5.72 |
| Analyst | Strong Buy |
| Ask | 4.18 |
| Volume | 50,264 |
| Avg. Volume (20D) | 149,696 |
| Open | 3.97 |
| Previous Close | 3.88 |
| Day's Range | 3.82 - 4.03 |
| 52-Week Range | 1.30 - 6.22 |
| Beta | 1.40 |
About XGN
Exagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. It enables rheumatologists to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables diff...
Industry Medical - Diagnostics & Research
Sector Healthcare
IPO Date Sep 19, 2019
Employees 209
Stock Exchange NASDAQ
Ticker Symbol XGN
Website https://www.exagen.com
Analyst Forecast
According to 2 analyst ratings, the average rating for XGN stock is "Strong Buy." The 12-month stock price forecast is $7.5, which is an increase of 86.01% from the latest price.
Stock ForecastsNext Earnings Release
Exagen Inc. is scheduled to release its earnings on May 12, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
7 months ago
+12.65%
Exagen shares are trading higher after the company...
Unlock content with
Pro Subscription
